New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 4, 2012
09:12 EDTDTEGY, S, PCS, MTN, PBY, ESIO, TEVA, GALE, TOL, BIG, DRIOn The Fly: Pre-market Movers
HIGHER AFTER EARNINGS: Big Lots (BIG), up 7.3%... Toll Brothers (TOL), up 4.6%... ALSO HIGHER: Galena Biopharma (GALE), up 15% after signing NeuVax commercialization partnership with Teva (TEVA)... Electro Scientific (ESIO), up 12% after declaring $2/share special dividend... LOWER AFTER EARNINGS: Pep Boys (PBY), down 8.7%... Vail Resorts (MTN), down 7.3%... ALSO LOWER: Darden (DRI), down 8.9% after warning on Q2, FY13 EPS... MetroPCS (PCS), down 6.6% after Reuters says Sprint (S) unlikely to counter T-Mobile's (DTEGY) bid.
News For DRI;BIG;TOL;GALE;TEVA;ESIO;PBY;MTN;PCS;S;DTEGY From The Last 14 Days
Check below for free stories on DRI;BIG;TOL;GALE;TEVA;ESIO;PBY;MTN;PCS;S;DTEGY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
September 4, 2014
07:21 EDTTEVAMedidata can obtain major new platform customers, says Stifel
Noting that Medidata (MDSO) partners with Veeva, Stifel believes that a number of Veeva (VEEV) customers could become Medidata platform customers, especially if they already use Medidata for R&D and clinical trial solutions. The firm identifies Merck (MRK), Gilead (GILD), and Teva (TEVA) as companies that may become platform clients for Medidata. Stifel keeps a $55 price target and Buy rating on Medidata.
September 3, 2014
17:44 EDTTOLToll Brothers looks unattractive, Barron's says
Subscribe for More Information
13:32 EDTDRIStarboard says Darden's decision to delay meeting 'poorly conceived' solution
Subscribe for More Information
11:07 EDTBIGOptions with decreasing implied volatility
Subscribe for More Information
08:12 EDTSSprint will cut expenses further, says Wells Fargo
After meeting with Sprint's new CEO, Wells Fargo thinks the company will significantly cut its expenses. The firm expects the company to use some of the savings from these cuts for marketing and advertising, but it believes that the savings will exceed the additional expenditures. Wells keeps an Outperform rating on the stock.
06:16 EDTTOLToll Brothers sees FY14 revenue $3.76B-$3.99B, consensus $3.84B
Subscribe for More Information
06:14 EDTTOLToll Brothers sees Q4 home deliveries 1,710-1,910
Subscribe for More Information
05:59 EDTTOLToll Brothers reports Q3 EPS 53c, consensus 45c
Subscribe for More Information
05:44 EDTTEVATeva announces positive judgement in patent case against AstraZeneca
Subscribe for More Information
September 2, 2014
15:32 EDTTOLNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Toll Brothers (TOL), consensus 45c; Navistar (NAV), consensus (66c); G-III Apparel (GIII), consensus 16c; Vince Holding (VNCE), consensus 24c; Dorian LPG (LPG), consensus 1c.
14:45 EDTTOLToll Brothers September weekly volatility increases into Q3
Subscribe for More Information
14:16 EDTTOLToll Brothers technical comments before earnings
Subscribe for More Information
11:08 EDTBIGOptions with decreasing implied volatilit
Subscribe for More Information
08:38 EDTDRIDarden announces new director nominees for annual meeting of shareholders
Subscribe for More Information
08:34 EDTDRIDarden backs FY15 adjusted EPS $2.22-$2.30, consensus $2.22
Subscribe for More Information
08:34 EDTDRIDarden reports progress on its Olive Garden brand renaissance plan
Subscribe for More Information
08:33 EDTDRIDarden sees Q1 adjusted 31c-33c, consensus 30c
Subscribe for More Information
08:30 EDTBIGBig Lots price target raised to $59 from $49 at FBR Capital
Subscribe for More Information
08:02 EDTTEVATeva reports statistically significant results in reslizumab trial
Teva Pharmaceutical Industries announced that reslizumab, an investigational anti-IL-5 monoclonal antibody, demonstrated clear levels of efficacy in achieving the primary endpoint of reduction in the frequency of clinical asthma exacerbations compared to placebo in two pivotal Phase III studies in patients with inadequately controlled moderate to severe asthma with elevated levels of blood eosinophils. In both trials, reslizumab treatment showed both clinically relevant and statistically significant reductions in the frequency of CAE compared to placebo. Reslizumab has also demonstrated a positive effect on lung function and asthma control in the Phase III program . The combination of an effect on clinically important exacerbations and on improvements and preservation of lung function suggest that reslizumab may be a uniquely differentiated treatment for patients with moderate to severe asthma with elevated levels of blood eosinophils. This initial set of results shows the adverse event profile of reslizumab was comparable to placebo in both trials. The incidence of common AEs was consistent with those seen in a moderate to severe asthma population, the most frequent being upper respiratory tract infections, asthma and headache. Further analyses of additional efficacy and safety data are ongoing. These new data are from two global Phase III 12-month, randomized, double-blind, placebo-controlled, parallel-group studies, evaluating the efficacy and safety of intravenously administered reslizumab once every four weeks, compared to placebo in asthma patients that are inadequately controlled by standard of care therapy.
07:39 EDTSSoftbank to launch robot in U.S. Sprint stores, Bloomberg reports
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use